Artiva Biotherapeutics

Artiva Biotherapeutics

Artiva’s lead program, AlloNK®, is an off-the-shelf, natural killer (NK) cell therapy candidate designed to drive B-cell depletion in combination with monoclonal antibodies. AlloNK® is currently in clinical trials for treatment of systemic lupus erythematosus and lupus nephritis, and in an investigator-initiated basket trial in multiple autoimmune indications including rheumatoid arthritis, certain forms of ANCA-vasculitis, and pemphigus vulgaris. AlloNK® is also being developed in combination with Affimed’s acimtamig (AFM13) in relapsed/refractory CD30-positive lymphomas. Artiva’s mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Artiva is headquartered in San Diego.